Ascendis presents data from phase II trial of rare hormone disease treatment
Danish Ascendis Pharma has announced week-84 data from its TransCon PTH product study within the rare endocrine disorder hypoparathyroidism.
BY ANDREAS LØNSTRUP, TRANSLATED BY DANIEL PEDERSEN
Ascendis Pharma, which is based in Denmark, is ready to present top-line results from week 84 of its phase II trial with its drug candidate Transcon PTH against the rare endocrine disorder hypoparathyroidism, which affects the level of parathyroid hormone in patients, it reports in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
